### Table 1.103C  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 12 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 12 or Older: Standard Errors of Numbers in Thousands, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>369</td>
<td>375</td>
<td>191</td>
<td>178</td>
<td>194</td>
<td>180</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>305</td>
<td>323</td>
<td>186</td>
<td>171</td>
<td>189</td>
<td>173</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>146</td>
<td>131</td>
<td>179</td>
<td>167</td>
<td>181</td>
<td>169</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>157</td>
<td>140</td>
<td>33</td>
<td>28</td>
<td>33</td>
<td>28</td>
</tr>
<tr>
<td>Provigil®</td>
<td>72</td>
<td>56</td>
<td>26</td>
<td>29</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant⁽¹⁾</td>
<td>157</td>
<td>148</td>
<td>32</td>
<td>26</td>
<td>32</td>
<td>26</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

⁽¹⁾ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.103D  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 12 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 12 or Older: Standard Errors of Percentages, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.14</td>
<td>0.14</td>
<td>0.07</td>
<td>0.06</td>
<td>0.86</td>
<td>0.87</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.11</td>
<td>0.12</td>
<td>0.07</td>
<td>0.06</td>
<td>0.99</td>
<td>1.03</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.11</td>
<td>0.11</td>
<td>0.07</td>
<td>0.06</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
<td>0.02</td>
<td>1.78</td>
<td>1.67</td>
</tr>
<tr>
<td>Provigil® (1)</td>
<td>0.06</td>
<td>0.05</td>
<td>0.01</td>
<td>0.01</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant(1)</td>
<td>0.06</td>
<td>0.05</td>
<td>0.01</td>
<td>0.01</td>
<td>1.09</td>
<td>0.96</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

1 Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.103P  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 12 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 12 or Older: P Values from Tests of Differences of Percentages, 2018 Versus 2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.1563</td>
<td>0.2046</td>
<td>0.0023</td>
<td>0.0011</td>
<td>0.0128</td>
<td>0.0024</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td></td>
<td></td>
<td>0.0025</td>
<td>0.9920</td>
<td>0.4986</td>
<td>0.4970</td>
</tr>
<tr>
<td>Provigil®</td>
<td></td>
<td></td>
<td>0.0645</td>
<td>0.2852</td>
<td>0.2745</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.3583</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.104C  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 12 to 17 and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 12 to 17: Standard Errors of Numbers in Thousands, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>62</td>
<td>62</td>
<td>34</td>
<td>27</td>
<td>34</td>
<td>28</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>59</td>
<td>58</td>
<td>33</td>
<td>27</td>
<td>34</td>
<td>27</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>51</td>
<td>51</td>
<td>33</td>
<td>25</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>36</td>
<td>35</td>
<td>17</td>
<td>13</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>Provigil®</td>
<td>14</td>
<td>9</td>
<td>6</td>
<td>3</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

 Definitions: Measures and terms are defined in Appendix A.

 Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.104D  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 12 to 17 and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 12 to 17: Standard Errors of Percentages, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.25</td>
<td>0.25</td>
<td>0.14</td>
<td>0.11</td>
<td>1.61</td>
<td>1.42</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.24</td>
<td>0.23</td>
<td>0.13</td>
<td>0.11</td>
<td>1.76</td>
<td>1.55</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.21</td>
<td>0.21</td>
<td>0.13</td>
<td>0.10</td>
<td>2.12</td>
<td>1.86</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.15</td>
<td>0.14</td>
<td>0.07</td>
<td>0.05</td>
<td>2.69</td>
<td>2.25</td>
</tr>
<tr>
<td>Proviron®</td>
<td>0.06</td>
<td>0.04</td>
<td>0.02</td>
<td>0.01</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant1</td>
<td>0.02</td>
<td>0.03</td>
<td>0.01</td>
<td>0.01</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant</td>
<td>0.10</td>
<td>0.10</td>
<td>0.03</td>
<td>0.02</td>
<td>2.08</td>
<td>1.62</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

1 Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.7198</td>
<td></td>
<td>0.0597</td>
<td>0.0496</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.8214</td>
<td></td>
<td>0.0727</td>
<td>0.0522</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.6618</td>
<td></td>
<td>0.0518</td>
<td>0.0312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.0508</td>
<td></td>
<td>0.3780</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.7039</td>
<td></td>
<td>0.9493</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>0.8694</td>
<td></td>
<td>0.5588</td>
<td>0.5779</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.105C  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 18 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 18 or Older: Standard Errors of Numbers in Thousands, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate</td>
<td>366</td>
<td>368</td>
<td>190</td>
<td>175</td>
<td>192</td>
<td>177</td>
</tr>
<tr>
<td>Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>299</td>
<td>316</td>
<td>185</td>
<td>169</td>
<td>187</td>
<td>170</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>294</td>
<td>299</td>
<td>177</td>
<td>164</td>
<td>179</td>
<td>166</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>144</td>
<td>127</td>
<td>71</td>
<td>57</td>
<td>71</td>
<td>58</td>
</tr>
<tr>
<td>Provigil®</td>
<td>157</td>
<td>139</td>
<td>32</td>
<td>27</td>
<td>32</td>
<td>27</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>72</td>
<td>56</td>
<td>25</td>
<td>29</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>155</td>
<td>146</td>
<td>31</td>
<td>25</td>
<td>31</td>
<td>25</td>
</tr>
</tbody>
</table>

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.105D  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 18 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 18 or Older: Standard Errors of Percentages, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td>0.15</td>
<td>0.15</td>
<td>0.08</td>
<td>0.07</td>
<td>0.95</td>
<td>0.95</td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.12</td>
<td>0.13</td>
<td>0.07</td>
<td>0.07</td>
<td>1.11</td>
<td>1.14</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.12</td>
<td>0.12</td>
<td>0.07</td>
<td>0.07</td>
<td>1.16</td>
<td>1.21</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.06</td>
<td>0.05</td>
<td>0.03</td>
<td>0.02</td>
<td>2.06</td>
<td>2.00</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.06</td>
<td>0.06</td>
<td>0.01</td>
<td>0.01</td>
<td>1.34</td>
<td>1.11</td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.03</td>
<td>0.02</td>
<td>0.01</td>
<td>0.01</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant†</td>
<td>0.06</td>
<td>0.06</td>
<td>0.01</td>
<td>0.01</td>
<td>1.19</td>
<td>1.05</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

† Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td>0.1728</td>
<td>0.2166</td>
<td>0.1620</td>
<td>0.1996</td>
<td>0.8720</td>
<td>0.2662</td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.0062</td>
<td>0.0031</td>
<td>0.0073</td>
<td>0.1199</td>
<td>0.5808</td>
<td>0.4983</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.0318</td>
<td>0.0082</td>
<td>0.0372</td>
<td>0.3471</td>
<td>0.5483</td>
<td>0.4064</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.5808</td>
<td>0.3471</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.5483</td>
<td>0.4064</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Other Prescription Stimulant</td>
<td>0.4983</td>
<td>0.4064</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

1 Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.106C  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 18 to 25 and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 18 to 25: Standard Errors of Numbers in Thousands, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td>129</td>
<td>127</td>
<td>99</td>
<td>93</td>
<td>108</td>
<td>104</td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>127</td>
<td>124</td>
<td>98</td>
<td>92</td>
<td>107</td>
<td>103</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>122</td>
<td>118</td>
<td>97</td>
<td>88</td>
<td>105</td>
<td>99</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>60</td>
<td>64</td>
<td>38</td>
<td>42</td>
<td>39</td>
<td>43</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>24</td>
<td>24</td>
<td>11</td>
<td>7</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Provigil®</td>
<td>11</td>
<td>12</td>
<td>7</td>
<td>9</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>38</td>
<td>38</td>
<td>11</td>
<td>5</td>
<td>11</td>
<td>5</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.106D  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 18 to 25 and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 18 to 25: Standard Errors of Percentages, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.38</td>
<td>0.37</td>
<td>0.29</td>
<td>0.27</td>
<td>1.34</td>
<td>1.39</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.37</td>
<td>0.36</td>
<td>0.29</td>
<td>0.27</td>
<td>1.37</td>
<td>1.47</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.35</td>
<td>0.35</td>
<td>0.28</td>
<td>0.26</td>
<td>1.40</td>
<td>1.54</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.17</td>
<td>0.19</td>
<td>0.11</td>
<td>0.12</td>
<td>2.71</td>
<td>2.84</td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.07</td>
<td>0.07</td>
<td>0.03</td>
<td>0.02</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant(^1)</td>
<td>0.03</td>
<td>0.04</td>
<td>0.02</td>
<td>0.03</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

\(^*\) = low precision; \(\_\_\) = not available; \(da\) = does not apply; \(nc\) = not comparable due to methodological changes; \(nr\) = not reported due to measurement issues.

\(^1\) Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.106P  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 18 to 25 and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 18 to 25: *P Values from Tests of Differences of Percentages, 2018 Versus 2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.0026</td>
<td></td>
<td>0.0154</td>
<td>0.5950</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.0015</td>
<td></td>
<td>0.0161</td>
<td>0.7993</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.0002</td>
<td></td>
<td>0.0159</td>
<td>0.7678</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.7085</td>
<td></td>
<td>0.9589</td>
<td>0.8316</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provigil*</td>
<td>0.8438</td>
<td></td>
<td>0.0785</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Any Other Prescription Stimulant*</td>
<td>0.7361</td>
<td></td>
<td>0.4932</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.3024</td>
<td></td>
<td>0.2138</td>
<td></td>
<td>0.2708</td>
<td></td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

1 Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td>343</td>
<td>329</td>
<td>153</td>
<td>134</td>
<td>154</td>
<td>134</td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>269</td>
<td>273</td>
<td>146</td>
<td>126</td>
<td>148</td>
<td>126</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>262</td>
<td>258</td>
<td>138</td>
<td>125</td>
<td>139</td>
<td>125</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>127</td>
<td>109</td>
<td>60</td>
<td>39</td>
<td>60</td>
<td>39</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>153</td>
<td>137</td>
<td>30</td>
<td>27</td>
<td>30</td>
<td>27</td>
</tr>
<tr>
<td>Provigil®</td>
<td>71</td>
<td>54</td>
<td>24</td>
<td>27</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>151</td>
<td>140</td>
<td>29</td>
<td>24</td>
<td>29</td>
<td>24</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
Table 1.107D  Any Use and Misuse of Stimulant Subtypes in Past Year among Persons Aged 26 or Older and Misuse of Stimulant Subtypes in Past Year among Past Year Any Users of Stimulant Subtypes Aged 26 or Older: Standard Errors of Percentages, 2017 and 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.16</td>
<td>0.15</td>
<td>0.07</td>
<td>0.06</td>
<td>1.13</td>
<td>1.05</td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.13</td>
<td>0.13</td>
<td>0.07</td>
<td>0.06</td>
<td>1.46</td>
<td>1.37</td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.12</td>
<td>0.12</td>
<td>0.07</td>
<td>0.06</td>
<td>1.55</td>
<td>1.47</td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.06</td>
<td>0.05</td>
<td>0.03</td>
<td>0.02</td>
<td>2.92</td>
<td>2.48</td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.07</td>
<td>0.07</td>
<td>0.01</td>
<td>0.01</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>0.07</td>
<td>0.07</td>
<td>0.01</td>
<td>0.01</td>
<td>1.39</td>
<td>1.26</td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANY PRESCRIPTION STIMULANT</td>
<td>0.7850</td>
<td>0.0911</td>
<td>0.0847</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine or Methylphenidate Products</td>
<td>0.8913</td>
<td>0.0494</td>
<td>0.0126</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamine Products</td>
<td>0.8861</td>
<td>0.1197</td>
<td>0.0451</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylphenidate Products</td>
<td>0.2280</td>
<td>0.0589</td>
<td>0.1420</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectic (Weight-Loss) Stimulants</td>
<td>0.9037</td>
<td>0.9777</td>
<td>0.9509</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provigil®</td>
<td>0.2279</td>
<td>0.6122</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Other Prescription Stimulant¹</td>
<td>0.4455</td>
<td>0.5095</td>
<td>0.5987</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

¹ Includes use or misuse of stimulants containing other active ingredients. Reports of misuse of "any other prescription stimulant" that correspond only to the specific stimulant categories shown in the table are excluded from estimates for Any Other Prescription Stimulant and are included instead in the relevant stimulant category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2017 and 2018.